deltatrials
Completed PHASE1 NCT00004216

VNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Therapy

A Phase I Trial of a Live, Genetically Modified Salmonella Typhimurium (VNP20009) for the Treatment of Cancer by Intratumoral Injection

Sponsor: Vion Pharmaceuticals

Conditions Unspecified Adult Solid Tumor, Protocol Specific
Interventions cefixime ceftriaxone sodium ciprofloxacin salmonella VNP20009 trimethoprim-sulfamethoxazole
Updated 5 times since 2017 Last updated: Jul 17, 2013 Started: Aug 31, 1999 Completion: Jan 31, 2008

A PHASE1 clinical study on Unspecified Adult Solid Tumor, Protocol Specific, this trial is completed. The trial is conducted by Vion Pharmaceuticals and has accumulated 5 data snapshots since 1999. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1

    First recorded

Aug 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Vion Pharmaceuticals
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Boston, United States
  • • Cleveland, United States
  • • Dallas, United States